Need access to NeoLink? Contact your Sales rep or our Client Services team at 866.776.5907, Option 3

April 23, 2025

New HER2 Ultralow Scoring to be Included in HER2 Testing Services

Effective Monday, April 28th, HER2 testing services will include HER2 ultralow scoring in accordance with recent FDA guidelines and the evolving landscape of breast cancer treatment. This update will be incorporated into both our tech-only and global interpretation service offerings, ensuring your lab stays at the forefront of precision diagnostics.

To support a smooth transition, we will be releasing a recorded training video that walks you through the updated scoring criteria.

Stay tuned for the training release and thank you for trusting us as your diagnostic partner.

 

 

🎉 It’s Lab Week 2025! 🎉

Lab Week is all about honoring the incredible work of our lab professionals and the impact they make on patients’ lives every day. Let’s show our NEOSpirit and make this week unforgettable! Starting this week, we're kicking off the week with this special message from Warren Stone, President and Chief Operating Officer.

View video

 

NeoGenomics to attend the 2025 AACR Annual Meeting

Visit us at Booth #2449 to meet with members of the team to learn more about how NeoGenomics can be your premier partner, supporting all aspects of the drug development lifecycle, from discovery to commercialization. From clinical sample testing services to real-world multi-modal data solutions, NeoGenomics has you covered.

In addition, we are proud to announce that 6 abstracts will be presented utilizing NeoGenomics' broad portfolio of testing services.

Schedule a meeting with one of our Neo colleagues!

 

NeoGenomics to attend the 2025 Community Oncology Conference (COA)

NeoGenomics will be exhibiting at the 2025 Community Oncology Conference taking place in Orlando, Florida starting April 29th. Stop by Booth #121 and meet the team.

To serve our customers and their patients, we evaluate our test menu regularly to align with clinical guidelines. Effective May 12th, we will improve our test offerings to serve your diagnostic needs. While specific tests will be discontinued, we have thoroughly evaluated and identified more appropriate tests from our menu that align with recommended guidelines. Below is a comprehensive list of affected tests and their recommended replacements.

Orders for the NeoTYPE^® Discovery Profile and replaced tests will not be automatically converted. Please order the new test using the appropriate requisition form or the online ordering portal to avoid testing delays.

For a complete list of test updates, click here.